The Latest Cardiac and Vascular News
Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs Data to be Presented Today at the American College of Cardiology 71st Annual Scientific Session & Expo CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, a biotechnology company pioneering a new […]
MOUNTAIN VIEW, Calif., April 04, 2022 (GLOBE NEWSWIRE) — HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced that Monica Tellado has been appointed Chief Financial Officer (CFO), effective April 4, 2022. “Monica is a high-impact leader with an outstanding track record of delivering results and creating value,” said […]
AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of amyloid Sensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in AL Cardiac uptake was also observed in eleven patients who had not previously been diagnosed with cardiac disease SAN FRANCISCO, April […]
Treatment with mavacamten showed sustained improvement in left ventricular outflow tract (LVOT) gradients, New York Heart Association (NYHA) Class and N-terminal pro brain natriuretic peptide (NT-proBNP) levels At 48 and 84 Weeks, Mavacamten safety was consistent with that seen in the EXPLORER-HCM study Interim results were presented as a late-breaking […]
– Data to Be Presented at 2022 ACC Annual Meeting Demonstrate Valve Disease is More Common in Women in the U.S. – – Other Key Findings Suggest Tricuspid and Mitral Regurgitation Have Highest Prevalence Rates; Severe Mitral Regurgitation Diagnosed More Frequently in Centers Offering Percutaneous Mitral Therapies – ALISO VIEJO, Calif.–(BUSINESS […]
Results presented on April 2nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22) Trial achieved primary reversal endpoint in older volunteers Bentracimab was well tolerated in the Phase 2b trial, with no drug-related serious adverse events or thrombotic events reported MALVERN, […]
GENT, Belgium–(BUSINESS WIRE)–FEops today announced that it received authorization from the U.S. Food and Drug Administration (FDA) for FEops HEARTguide™ pre-operative planning of left atrial appendage occlusion (LAAo) with the Abbott’s Amplatzer™ Amulet™ and Boston Scientific’s Watchman FLX™ device*. FEops HEARTguide is a one-in-its-kind cloud-based procedure planning solution in the structural […]
– SLN360 reduced Lp(a) – a key genetic risk factor for heart disease – by up to 98% with reductions of up to 81% persisting at 150 days – Results were simultaneously published in The Journal of the American Medical Association (JAMA) LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), […]
Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure patients while on guideline-recommended RAASi therapy Veltassa® prevented the recurrence of hyperkalemia events, potentially leading to better patient outcomes Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure […]
ACC.22: Late-breaking data show CoreValveTM and EvolutTM is the only platform to out-perform surgery in valve durability at five years Medtronic today unveiled new insights from a pooled analysis of high and intermediate risk patients from the CoreValve/Evolut program, showing a lower occurrence in structural valve deterioration (SVD) in patients […]
